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INTRODUCTION 
The pleuropulmonary complications associated 
with collagen vascular diseases are frequently 
recorded 1.  The involvement may be subclinical, 
but its true extent may be masked by exercise 
limitation due to musculoskeletal features of the 
connective tissue disease2. Although most 
pulmonary complications appear in an established 
case of a collagen vascular disease, in some 
situations, the lung disease precedes the more 
typical manifestations3.  
Abnormalities of pulmonary functions have 
been found in children with collagen diseases even 
in the absence of clinical or radiographic evidence 
of pulmonary involvement. However, it is not 
known whether they represent an early sign of 
progressive lung disease which is not clinically 
evident or they are associated with disease activity4. 
The increasing incidence of lung involvement of 
most of collagen vascular diseases is primarily due 
to increased recognition aided by the use of 
spirometry, lung volume measurement, 
bronchoalveolar lavage and computed tomography 
which can detect abnormalities even in 
asymptomatic patients5. 
This work aimed at evaluation of the clinical 
and functional characteristics of the lung in children 
with SLE and JRA using pulmonary function tests 
(PFTs) and high resolution computed tomography 
(HRCT) of the chest. The relation of pulmonary 
involvement to the type and duration of disease was 




Background: Alveolar and airway injury represent one of the most 
common features of rheumatological diseases and is believed to have a 
significant impact on the course of these diseases.  
Objective: This work aimed at evaluating airway and alveolar 
involvement in children with systemic lupus erythematosus (SLE) and 
juvenile rheumatoid arthritis (JRA).  
Methods: Thirty four children (21 with SLE and 13 with JRA) were 
assessed by pulmonary function tests (PFTs) namely spirometry and 
carbon monoxide diffusion capacity (DLCO) in comparison to 10 healthy 
controls, as well as by plain roentgenography and high resolution 
computed tomography (HRCT) of the chest.  
Results: The studied patients had significantly lower mean PFT values as 
compared to controls. A restrictive pattern of PFTs was more common as 
it was detected in 62% of patients with SLE and 23% of those with JRA 
whereas an obstructive pattern was detected in 14% and 8% respectively. 
Significantly lower FEF 25-75% values were detected in symptomatic 
patients. Low values of DLCO (less than 80% of predicted) were recorded 
in 60% of the studied patients. Chest HRCT was abnormal in 68% of 
studied patients. In SLE, ground glass appearance and pleural 
irregularity were the most common findings whereas in JRA, bronchial 
wall thickening, mosaic appearance and air trapping were prominent. 
Abnormal findings were detected in 5/9 of asymptomatic patients.  
Conclusion: airway and alveolar abnormalities are frequently 
encountered in children with SLE (95%) and JRA (85%) even if they are 
asymptomatic. HRCT and pulmonary function tests including diffusion 
studies are recommended as useful tools for the diagnosis and early 
detection of pulmonary involvement in these patients. 
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METHODS 
The study was conducted in the Pediatric Allergy 
and Immunology, Pediatric Pulmonary Function, 
and Radiology Units of Ain Shams University, 
Cairo, Egypt during the period from October 2001 
to October 2002. 
Patients:  
The study included 34 patients (21 with SLE and 13 
with JRA). They were 7 males and 27 females with 
a mean age of (14.63± 3.28) years, and a mean 
disease duration of (4.73 ± 3.51) years. According 
to their diagnosis, patients were classified into: 
Group of SLE:  
It included 21 patients with SLE fulfilling the 
American Rheumatism Association (ARA) revised 
Criteria for diagnosis of SLE 6. They were 2 males 
and 19 females with a mean age of 15.3±2.54 years, 
and mean disease duration of 4.76±3.66 years. 
Disease severity was assessed using the SLEDAI 
score7. All patients were under long-term oral 
prednisolone in a dose ranging from 0.5-2 
mg/kg/day (maximum dose 60mg/m2/day). Five 
patients were receiving monthly pulse 
cyclophosphamide therapy. 
Group of JRA:  
It included 13 patients with JRA fulfilling the ARA 
revised criteria for diagnosis of rheumatoid 
arthritis8. They were 5 males and 8 females, with a 
mean age of 13.57±4 years, and mean disease 
duration of 4.68±3.4 years. Eight of them were of 
the polyarticular-onset type, 3 had pauciarticular-
onset JRA and 2 had systemic-onset JRA. All 
patients were receiving NSAIDs. In addition, seven 
were on oral prednisolone, and three were on oral 
methotrexate (10 mg/m2/wk). 
Ten clinically healthy children age and sex 
matched to the patients, were studied as a control 
group. They were 4 males and 6 females, with a 
mean age of 14.2±1.99 years. 
Methods:  
The patients were assessed clinically for pulmonary 
involvement. Symptoms such as dyspnea, cough, 
hemoptysis and recurrent attacks of chest infection 
were recorded. General and local signs of lung 
diseases such as clubbing, cyanosis, chest deformity 
and limited expansion, diminished air entry, or the 
presence of rhonchi or rales, were sought. 
 
Routine laboratory investigations  
Included complete blood picture by Coulter 
Counter (Coulter Instruments, Model T660, 
Fullerton, California, USA), ESR by the 
Westergren method, ANA and anti dsDNA by 
indirect immunofluorescent microscopy (IMMCO 
Diagnostics, USA), serum rheumatoid factor by 
latex agglutination (Avitex-RF; Omega 
Diagnostics, Alloa, UK) and complement 3 and 4 
by turbidimetry (Turbiquant; Behring Diagnostics 
GmbH, Marburg, Germany). 
 
Pulmonary function tests (PFTs) 9  
(Med-Graphics 1070 series 2E/105). The data 
obtained were: 
- Spirometry 
• FVC: forced vital capacity (liter/min). 
• FEV1: forced respiratory volume in the first 
second (liter/min). 
• FEV1%: FEV1/FVC 
• MVV: maximum voluntary ventilation 
(liter/min). 
• RV: residual volume (liter/min). 
• SVC: slow vital capacity (liter/min). 
• FEF25-75%: forced expiratory flow at 25-75% 
of FVC. 
For every parameter, actual and predicted 
values for age, sex, height and weight were 
obtained and the percentages from predicted values 
were calculated. The results of spirometric 
pulmonary functions were categorized as:  
 - Normal if values lie between 80-120% of 
predicted. 
 - Obstructive if FEV1% is < 85%. 
 - Restrictive if FEV1% is > 85%. 
- Carbon Monoxide Diffusion capacity (DLCO): 
Through a single breath test, DLCO was assessed 
for controls and for 13 patients with SLE and 10 
with JRA. DLCO was considered abnormal if it was 
below 80% of the predicted value. 
Exclusion criteria for PFTs were age below 5 
years, presence of a cardiac problem, or a 
hemoglobin concentration below 8 gm/dl, all of 
which would affect the results.  
 
Radiological assessment of patients by: 
- Plain chest X-ray (CXR) postero-anterior view to 
evaluate lung fields. 
- High-resolution computed tomography (HRCT) of 
the chest using General Electric Prospeed VX 
Scanner. While lying in supine position with arms 
above heads, patients were scanned at maximal 
inspiration during suspended respiration to promote 
separation of pulmonary parenchymal structures.  
Axial 1-2 mm thin sections were obtained every 
10mm, using an FOV of 25-28, 140 KV, 170 MA, 
and 3 second scan time. Data are reconstructed with 
bone algorithm to preserve sharp edges of the fine 
details of the lung parenchyma. Scans were imaged 
at window width (WW) of 1200 and window level 
(WL) of -60010. 
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Statistical methods:  
Analysis of the results was done via SPSS computer 
software version 8 (Statistical Package of Social 
Science) employing mean and standard deviation as 
descriptive tools and student's T test, Mann-
Whitney U test, Chi square test and Pearson's 
correlation for comparisons. Results were 
considered significant at a p value of <0.05. 
 
RESULTS 
Comparing the studied groups as regards 
demographic data revealed absence of any statistical 
significant difference between them except for the 
duration of illness, which was statistically higher in 
symptomatic patients with JRA compared to the 
asymptomatic ones (Table 1).   
Abnormal spirometric PFTs were recorded in 
58% of all studied patients (71% of SLE patients, 
and 31% of JRA patients). A high percentage of 
patients with SLE and JRA had restrictive pattern 
of PFTs (62% and 23% respectively) whereas an 
obstructive pattern was detected in 14% and 8% 
respectively.  
The mean values of FVC, FEV1, MVV and 
DLCO were significantly lower in patients with 
SLE and JRA in comparison to controls (Table 2). 
Apart from a significantly lower mean FEV1 in 
SLE, comparable PFT results were obtained in both 
patients' groups. SLEDAI (mean ± SD = 11.4 ± 6.8) 
correlated negatively, though insignificantly, with 
FEF25-75% and with DLCO (p>0.05). There existed a 
significant negative correlation between duration of 
illness and FEV1 in JRA (r -0.54, p<0.05) 
Clinically manifest pulmonary problems were 
encountered in 77% of patients with JRA and in 
71.4% of patients with SLE. The mean values of 
PFT results were largely comparable among 
symptomatic and asymptomatic patients of both 
groups (SLE and JRA) except for a significantly 
lower FEF25-75% in symptomatic patients (Fig.1). 
 
 
Figure 1: Forced expiratory flow at 25-75% of 
forced vital capacity (FEF25-75%) in symptomatic 
versus asymptomatic patients (values are given as 
mean±SD). 
Abnormal HRCT findings were detected in 5/9 
of the asymptomatic patients. In patients with SLE, 
the most common HRCT findings were ground 
glass appearance (Fig 2), mosaic appearance, 
pleural irregularity, and bronchial wall thickening. 
However, in JRA patients, bronchiolar wall 
thickening (Fig 3) was the most prominent finding 
followed by mosaic appearance (Fig 4) and air 
trapping (Table 3). Prominent atelectasis may also 
be seen in SLE as in Fig 5. Pulmonary nodules were 
detected in 3 SLE and 1 JRA patients. Pleural 
effusion was found in a patient with active JRA. 
HRCT was able to detect a greater percentage 
of patients with pulmonary involvement in the 
studied groups compared to plain chest x-ray (Table 
4). The only significant difference in the 
frequencies of abnormal findings between SLE and 




Table (1): Statistical comparison between studied groups as regards some demographic data 
 
2BSLE patients  
3B(n=21) 



















t = 0.51                  P= 0.60 t = 2.14                 P= 0.054 









t = 0.76                 P= 0.46 t = 0.65                  P= 0.53 










t = 0.64                 P= 0.53 t = 2.84             P= 0.049??/ 
Pulmonary Involvement in SLE and JRA. 
11 
 
Table (2): Pulmonary function tests (PFTs) as % predicted in patients with JRA and SLE versus controls.     
PFTs 
% of  
predicted 
Control JRA SLE 
Mean ± SD Mean ± SD t P Mean ± SD t P 
FVC 94.7 ± 8.05 77.3 ± 90.4 4.79 0.00* 71.09 ± 15.05 4.6 0.00* 
FEV1# 99.1 ±  9.4 81.46 ±  8.8 4.63 0.00* 71.67 ± 16.26 4.9 0.00* 
FEV1% 91.7 ± 6.4 877.25 ±  2.7 2.12 0.57 88.3 ± 6.25 1.4 0.17 
SVC 97.5 ± 12.5 91.18 ± 18.7 0.93 0.36 84.57 ± 16.12 2.2 0.04* 
RV 80 ± 27.2 75.38 ± 35.9 0.04 0.96 85.81 ± 72.37 0.4 0.68 
FEF25-75% 98 ± 23.9 97.15 ± 22.6 0.09 0.93 85.6 ± 29.5 1.2 0.26 
0BMVV 118.9± 25.6 71.88 ± 15.7 4.27 0.00* 74.14 ± 12.39 3.9 0.003* 
1BDLCO 87.9 ± 7.9 75.7 ± 26.06 1.24 0.18 68.2 ± 26.7 2.52 0.024* 
* Significant 
# Borderline significantly low value in SLE compared to JRA (t=1.99, p = 0.05). 
FVC: forced vital capacity (liter/min). FEV1: forced respiratory volume in the first second (liter/min). FEV1%: FEV1/FVC.  
SVC: slow vital capacity (liter/min). RV: residual volume (liter/min). FEF25-75%: forced expiratory flow at 25-75% of FVC.  
MVV: maximum voluntary ventilation (liter/min). DLCO: lung diffusion capacity for CO. 
 
Table (3): High resolution computed tomography findings (HRCT) in relation to the presence  
or absence of clinically manifest pulmonary problems. 
HRCT 
Findings 









No. % No. % No. % No. % 
Ground glass appearance  5 33 2 33 - - - - 
Mosaic appearance 4 27 - - 3 30 1 33 
Consolidation 3 20 2 33 1 10 - - 
Pulmonary nodules 3 20 - - 1 10 - - 
Interlobular septal thickening 2 13 - - - - - - 
Interstitial thickening 2 13 1 17 - - - - 
Bronchial wall thickening 4 27 - - 3 30 2 67 
Atelectatic bands 1 7 - - - - - - 
Air trapping 2 13 2 33 4 40 - - 
Cylindrical bronchiectasis - - - - 1 - 1 33 
Pleural irregularity 4 27 2 33 - - - - 
Pleural effusion - - - - 1 10 - - 
 
Table (4): Percentage of abnormal HRCT, spirometric PFTs, DLCO, and plain chest roentgenogram  
findings in patients with SLE and JRA. 
4BVariable SLE patients  (n=21) 




N % N % N % 
Spirometry 15 71* 4 31 19 56 
DLCO 9/13 69 6/10 60 15/23 65 
CXR# 2 10 1 8 3 9 
HRCT 15 71 9 69 23 68 
* Frequency of patients with abnormal spirometry in SLE versus JRA: X2=32, p=0.00. 
# Percent abnormal findings by CXR versus by spirometry, DLCO or HRCT both in SLE and JRA: P=0.00. 
HRCT= High resolution computed tomography, PFTs: pulmonary function tests, DLCO: lung diffusion capacity  








Figure (2): HRCT scan of a 16 years old female 
patient with SLE of 2 years duration. Bilateral 
diffuse hazy increased density (ground-glass 
appearance) is noticed.    
Figure (3): HRCT scan of a 12 years old male 
patient with JRA of 6 years duration. Bilateral 
bronchiolar wall thickening and ectasia are seen 





Figure (4): HRCT scan of a 10 years old female 
patient with JRA of 3 years duration showing a 
fairly triangular homogeneously dense area of 
consolidation seen at the right lateral basal 
segment. Similar smaller lesions are seen at the 
right anterior and posterior basal segments. Few 
variable sized bilateral subpleural nodules are 
also identified. Mild right sided pleural effusion 
extending into the right major fissure. Interstitial 
thickening and septal lines are also noted. 
Scattered patchy areas of decreased attenuation 
are noted (mosaic appearance). An arc-like 
atelectatic band is seen crossing the left anterior 
basal segment. 
Figure (5): HRCT scan of a 12 years old female 
patient with SLE of 4 years duration showing left 
apical y-shaped plate-like atelectatic band 
extending to the costal and mediastinal pleura.     
 
 
The overall pulmonary involvement, by all 
investigational measures, was 95% in SLE and 85% 
in JRA: 75% of the polyarticular-onset type, and 
100% of the pauciarticular- and systemic-onset 
types. 
DISCUSSION 
The increasing incidence of lung involvement in 
most of collagen vascular diseases is primarily due 
to increased recognition by different diagnostic 
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tools, which can detect abnormalities even in 
asymptomatic patients. However, the pattern of 
involvement varies with each connective tissue 
disease 5. 
This work revealed statistically significant 
lower values of PFTs (FVC, FEV1 and MVV) in 
the studied patients compared to the control group 
(P<0.05). This was more prominent in SLE than in 
JRA (76% and 30% respectively showed abnormal 
PFTs). In SLE, a higher SLEDAI tended to be 
associated with lower PFTs, namely FEF25-75% and 
DLCO. However, in JRA, impaired PFTs was more 
commonly linked to a longer duration of illness. 
Varying percentages of abnormal PFTs were 
recorded by several investigators 11-13. The variation 
could be attributed to different clinical characters of 
the studied groups as the duration of illness, disease 
severity, and whether they have symptomatic chest 
problems.  
A restrictive pattern of PFTs was recorded in 
62% of the studied SLE patients, and in 23% of 
those with JRA. This was supportive to the results 
of earlier studies 14,15 . The restrictive pattern of 
PFTs is either the result of parenchymal impairment 
due to interstitial connective tissue involvement, or 
is due to weakness of the respiratory muscles 9 
caused by phrenic nerve conduction abnormalities 
with secondary weakness of the diaphragm as 
explained by Trapani and associates 15. These 
pathologies are expected to occur more frequently 
in SLE. 
In the current study obstructive pattern of PFT 
was detected in 14% of SLE and 8% in JRA 
patients. DuBois and Wells 2 explained the 
obstructive pattern of PFT in patients with 
rheumatological diseases by external compression 
of bronchioles by hyperplastic lymphoid follicles 
“follicular bronchiolitis” or destruction of the 
bronchiolar wall and its replacement by fibrous 
tissue “bronchiolitis obliterans”.  
Diffusion studies showed significantly lower 
mean values in the studied patients compared to 
controls and the values were reduced in 69% of 
patients with SLE and 50% of those with JRA. This 
was in agreement with the results of previous 
investigators 15-19. Reduced DLCO could be 
attributed to loss of functioning alveolar –capillary 
bed with decreased lung volume or to 
microvascular changes 11. Some investigators 
correlated the reduced DLCO to increase secretion 
of some cytokines e.g. connective tissue growth 
factor 20 or surfactant D 21. 
In the present study, 26% of patients were 
chest-wise clinically free. McDonagh and 
associates 22 attributed the delay in appearance of 
chest symptoms in JRA-patients to their limited 
exercise level by arthritis. Five out of the 9 
asymptomatic patients (55.5%) showed abnormal 
HRCT (ground-glass appearance, consolidation, 
air-trapping, and bronchial wall thickening) despite 
having normal chest roentgenograms and PFTs.  
Previous investigators also recorded abnormal 
HRCT in patients with no signs or symptoms of 
pulmonary disease 1, 22-24. This observation 
highlights the importance of screening patients with 
connective tissue diseases for pulmonary 
abnormalities regardless the absence of clinically 
manifest pulmonary disease. 
Pulmonary involvement was frequent both in 
SLE and JRA (95% and 85% respectively) and its 
detection was best with HRCT (68% of all the 
studied patients) followed by DLCO and spirometry 
(65% and 56%). Chest roentgenograms were 
abnormal in only 9% of the studied patients. The 
higher percentage of pathologic findings at HRCT 
in patients with normal chest radiographs could be 
explained by the fact that pathologic HRCT 
findings are too discrete to be seen on chest 
radiographs. Perez and associates 1 found that 
HRCT depicted features of small airway disease in 
20 of the studied 33 patients with RA with normal 
PFTs, and concluded that HRCT is a more sensitive 
mean of detecting small airway disease than PFTs. 
They added that this could be explained by the 
likelihood of patchy basal interstitial disease which 
does not significantly impair overall pulmonary 
function.  
Previous reports on the role of tomography in 
the imaging of systemic collagen vascular diseases 
indicated that neither the nature nor the distribution 
of tomography findings in this group of disorders is 
reliably specific for a particular disease 12. In the 
current study, HRCT showed a range of 
abnormalities among the studied patients. The most 
frequently detected HRCT abnormality in patients 
with SLE was the ground glass appearance (33%) 
which is suggestive of active alveolitis. Salaffi and 
coworkers 24 emphasized the relationship between 
the cellularity of lower respiratory tract as assessed 
by BAL, and the ground glass pattern of HRCT 
scan. Bankier and associates 23 reported that ground-
glass attenuation most commonly reflects an active 
inflammation and is thus a reversible process, or 
may also result from changes that follow the acute 
phase of lung injury in the form of very fine 
intralobular fibrosis that lies below the limits of 
resolution of the CT scanner, and is therefore 
depicted as an amorphous increase in lung 
attenuation. They found that the most common 
abnormal HRCT findings are interlobular septal 
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thickening and intralobular interstitial thickening 
(33% for each finding). Fenlon and associates 12 and 
Sant and associates 25 found HRCT abnormalities 
suggestive of interstitial lung disease in 32% and 
38% of their patients respectively. Concerning JRA, 
the most common abnormal HRCT finding was 
bronchial wall thickening (38%), followed by air 
trapping and mosaic appearance (34% for each 
finding).  In a study on adult onset RA, air trapping 
was the most common HRCT finding (32% of 
patients) 1.  
In the present study, pulmonary nodules were 
detected, on HRCT, in 4 patients (3 with SLE and 1 
with rheumatoid factor positive JRA). Worth 
mentioning is that the recognition of small nodules 
is rather difficult, being easily missed between 
HRCT sections, and when present, are difficult to 
distinguish from blood vessels. Seaton 26 noted that 
nodules occasionally appear in patients without 
rheumatoid disease. There seems to be an 
association between the presence of subcutaneous 
nodules and the positivity of rheumatoid factor in 
JRA.  
Pleural abnormalities are less common than 
previously suggested and were elicited in 7 patients: 
6 (28%) with SLE (pleural thickening), and one 
(8%) with systemic-onset JRA (effusion). Effusions 
usually occur with disease flares as is the case with 
our JRA patient whereas pleural irregularities 
represent the consequence of poor control of such 
flares.  
In conclusion, lung involvement is a frequent 
finding in patients with SLE and JRA even if they 
are asymptomatic. This tended to correlate with 
disease severity in SLE and with disease duration in 
JRA. HRCT of the chest and PFTs give better 
insight onto the degree of pulmonary abnormalities, 
and are recommended as useful tools for the early 
detection of subclinical pleuropulmonary 
involvement in these patients. 
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